

SUPPLEMENTARY INFORMATION 2

Clinical Pharmacokinetics

Population pharmacokinetic and pharmacodynamic modelling and simulation for nedosiran clinical development and dose guidance in pediatric patients with primary hyperoxaluria type 1

Steven Zhang^{1*}, Pablo Gamallo², Verity Rawson¹

1. Novo Nordisk Inc., Lexington, Massachusetts, United States
2. Novo Nordisk Pharma SA, Madrid, Spain

*Corresponding author: Steven Zhang, xvzn@novonordisk.com




Figure S1. Standard GOF plots of the updated Pop-PK model




Figure S2. VPCs for the updated Pop-PK model stratified by PH status

Dashed blue lines represent observed 5th and 95th percentiles, solid red line represent observed median, and shaded areas represent 95% confidence interval around the model predicted 5th, median, and 95th percentiles. X and Y-axis are on log scale.